Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LCPS
MCID: LMN005
MIFTS: 28

Lmna-Related Cardiocutaneous Progeria Syndrome (LCPS)

Categories: Cardiovascular diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section

MalaCards integrated aliases for Lmna-Related Cardiocutaneous Progeria Syndrome:

Name: Lmna-Related Cardiocutaneous Progeria Syndrome 58
Lcps 58

Characteristics:

Orphanet epidemiological data:

58
lmna-related cardiocutaneous progeria syndrome
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare skin diseases


Sources

Summaries for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section
MalaCards based summary : Lmna-Related Cardiocutaneous Progeria Syndrome, also known as lcps, is related to legg-calve-perthes disease. An important gene associated with Lmna-Related Cardiocutaneous Progeria Syndrome is LMNA (Lamin A/C). The drugs Tacrolimus and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and bone, and related phenotypes are hypertension and lipoatrophy

Sources

Related Diseases for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section

Diseases related to Lmna-Related Cardiocutaneous Progeria Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 legg-calve-perthes disease 10.0

Sources

Symptoms & Phenotypes for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section

Human phenotypes related to Lmna-Related Cardiocutaneous Progeria Syndrome:

58 31 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertension 58 31 hallmark (90%) Very frequent (99-80%) HP:0000822
2 lipoatrophy 58 31 hallmark (90%) Very frequent (99-80%) HP:0100578
3 hypertriglyceridemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002155
4 congestive heart failure 58 31 hallmark (90%) Very frequent (99-80%) HP:0001635
5 mitral regurgitation 58 31 hallmark (90%) Very frequent (99-80%) HP:0001653
6 emphysema 58 31 hallmark (90%) Very frequent (99-80%) HP:0002097
7 mitral valve calcification 58 31 hallmark (90%) Very frequent (99-80%) HP:0004382
8 premature graying of hair 58 31 hallmark (90%) Very frequent (99-80%) HP:0002216
9 hypercholesterolemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003124
10 intracranial hemorrhage 58 31 hallmark (90%) Very frequent (99-80%) HP:0002170
11 abnormality of the pulmonary artery 58 31 hallmark (90%) Very frequent (99-80%) HP:0004414
12 absent eyelashes 58 31 hallmark (90%) Very frequent (99-80%) HP:0000561
13 sparse hair 58 31 hallmark (90%) Very frequent (99-80%) HP:0008070
14 squamous cell carcinoma of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0006739
15 basal cell carcinoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002671
16 aortic valve stenosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001650
17 aortic root aneurysm 58 31 hallmark (90%) Very frequent (99-80%) HP:0002616
18 absent eyebrow 58 31 hallmark (90%) Very frequent (99-80%) HP:0002223
19 alopecia universalis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002289
20 scleroderma 58 31 hallmark (90%) Very frequent (99-80%) HP:0100324
21 premature skin wrinkling 58 31 hallmark (90%) Very frequent (99-80%) HP:0100678
22 abnormality of the intrahepatic bile duct 58 31 hallmark (90%) Very frequent (99-80%) HP:0011040
23 ventricular hypertrophy 58 31 hallmark (90%) Very frequent (99-80%) HP:0001714
24 papillary renal cell carcinoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0006766
25 pulmonary carcinoid tumor 58 31 hallmark (90%) Very frequent (99-80%) HP:0030445
26 coronary artery atherosclerosis 31 hallmark (90%) HP:0001677
27 aortic atherosclerotic lesion 31 hallmark (90%) HP:0012397
28 coronary atherosclerosis 58 Very frequent (99-80%)
29 aortic atherosclerosis 58 Very frequent (99-80%)
Sources

Drugs & Therapeutics for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section

Drugs for Lmna-Related Cardiocutaneous Progeria Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Pancrelipase Approved, Investigational Phase 4 53608-75-6
5 Immunologic Factors Phase 4
6 Immunosuppressive Agents Phase 4
7 Calcineurin Inhibitors Phase 4
8 pancreatin Phase 4
9
Timolol Approved Phase 3 26839-75-8 33624 5478
10
Mycophenolic acid Approved Phase 3 24280-93-1 446541
11
Fenofibrate Approved Phase 2, Phase 3 49562-28-9 3339
12
Atorvastatin Approved Phase 2, Phase 3 134523-00-5 60823
13 Anti-Arrhythmia Agents Phase 3
14 Adrenergic Antagonists Phase 3
15 Neurotransmitter Agents Phase 3
16 Adrenergic Agents Phase 3
17 Adrenergic beta-Antagonists Phase 3
18 Antihypertensive Agents Phase 3
19 Anticholesteremic Agents Phase 2, Phase 3
20 Antimetabolites Phase 2, Phase 3
21 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3
22 Lipid Regulating Agents Phase 2, Phase 3
23 Hypolipidemic Agents Phase 2, Phase 3
24
Verapamil Approved Phase 2 52-53-9 2520
25
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
26
Azathioprine Approved Phase 2 446-86-6 2265
27 Liver Extracts Phase 2
28 glucocorticoids Phase 2
29 Hormone Antagonists Phase 2
30 Antirheumatic Agents Phase 2
31 Hormones Phase 2
32 Antineoplastic Agents, Hormonal Phase 2
33 Anti-Inflammatory Agents Phase 2
34
Phenylalanine Approved, Investigational, Nutraceutical 63-91-2 6140
35
Tyrosine Approved, Investigational, Nutraceutical 60-18-4 6057
36
arachidonic acid Experimental 506-32-1 444899
37 Soy Bean
38 Trace Elements
39 Micronutrients
40 Vitamins
41 Omega 3 Fatty Acid
42 Caseins

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day. Completed NCT02961608 Phase 4 Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
2 A Prospective Multicenter Case-series of Patients Treated With the 2.4 mm Variable Angle LCP Two-Column Volar Distal Radius Plate ® Completed NCT01103297 Phase 4
3 Comparison of Pharmacokinetic (PK) Levels Before and After Conversion From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus (LCPT) in Diabetic Transplant récipients Recruiting NCT04496401 Phase 4 Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]
4 A Multi-Center Randomized Controlled Pilot Study of Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation Terminated NCT01693367 Phase 4
5 Surgical Plate Osteosynthesis of Distal Radius Fractures. Prospective Study of the Locking Compression Plate (LCP) Terminated NCT00205998 Phase 4
6 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
7 Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO) Completed NCT01438710 Phase 3 Prograf;LCP-Tacro
8 Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt. Completed NCT00817206 Phase 3 LCP-Tacro;Prograf
9 Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacroâ„¢ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant Completed NCT01187953 Phase 3 Prograf (tacrolimus);LCP-Tacro
10 Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt. Completed NCT01962922 Phase 3 LCP-Tacro;Tacrolimus -IR
11 A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia Completed NCT00664859 Phase 2, Phase 3 LCP-AtorFen
12 The Effectiveness of the Liverpool Care Pathway in Improving End of Life Care for Dying Cancer Patients in Hospital. A Cluster Randomised Trial. Completed NCT01081899 Phase 3
13 A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day Completed NCT00496483 Phase 2 LCP Tacro (tacrolimus);Prograf
14 A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day Completed NCT00608244 Phase 2 LCP Tacro;Prograf
15 A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-Tacroâ„¢ Tablets Once Daily and Prograf® Capsules Twice Daily in Adult De Novo Liver Transplant Patients Completed NCT00772148 Phase 2 LCP -Tacro;Prograf
16 A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia Completed NCT00504829 Phase 2 LCP-AtorFen;atorvastatin;fenofibrate
17 A Phase 2, Open-Label, Multi-Center, Randomized Trial To Demonstrate The Pharmacokinetics Of LCP-Tacroâ„¢ Tablets Once Daily and Prograf® Capsules Twice Daily In Adult De Novo Kidney Transplant Patients Completed NCT00765661 Phase 2 Tacrolimus (Tacroâ„¢);Prograf
18 Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacroâ„¢ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients Completed NCT01666951 Phase 2 LCP-Tacro tablets;Prograf
19 Improving Quality of Care for the Dying Patient in Hospice: A Quasi Experimental Trial in Liguria Region Completed NCT01470625 Phase 2
20 P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release Not yet recruiting NCT04489134 Phase 2 Treatment A;Treatment B;Treament C;Treatment D
21 A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis Terminated NCT00608894 Phase 2 LCP-Tacro (tacrolimus);Azathioprine
22 Comprehensive 12-week Lifestyle Change Program in Elderly Patients With Heart Failure Unknown status NCT02303275
23 Treatment of Reverse Oblique Intertrochanteric or Subtrochanteric Fractures With a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc) or Trochanteric Nails. A Multicenter Cohort Study Completed NCT01128868
24 A Study to Evaluate the Acceptability of a New Phenylalanine Free Infant Formula for Use in the Dietary Management of Phenylketonuria in Infants From Birth to 2 Year of Age With Regard to Product Tolerance and Adherence. Completed NCT03058848
25 A Study to Evaluate the Acceptability of PKU Explore, a Renovated Phenylalanine Free Second Stage Protein Substitute for Use in the Dietary Management of Phenylketonuria in Infants From 6 Months to 5 Years of Age With Regard to Product Tolerance and Adherence. Completed NCT03168399
26 A Prospective, Open-label, Post-marketing Observational Study to Document the Use of Soy-based Infant Formula With Low Chain Polyunsaturates (LCP) in Infants With Symptoms Suggestive to Cow's Milk Allergy Completed NCT01809951
27 The Effects of Extended Duration of Long-Chain Polyunsaturated Fatty Acid (LCP)-Supplementation on Neurological and Immunological Development in Toddlers Completed NCT00982462
28 Feeding Patterns and Practices in Young Children With PKU During the First Two Years of Life: Acceptability and Efficacy of a New Protein Substitute Completed NCT03913156
29 Treatment of Displaced Lateral Clavicle Fractures Using a Locking Compression Plate With Lateral Extension - Clinical Observational Study Completed NCT02256059
30 Mid-term Outcome Following Revision Surgery of Clavicular Non- and Malunion Using Anatomic Locking Compression Plate and Iliac Crest Bone Graft Completed NCT02951468
31 Outcome After Polyaxial Locking Plate Osteosynthesis in Proximal Tibia Fractures: a Prospective Clinical Trial Completed NCT04680247
32 Sternal Fracture Fixation by Locking Compression Plates (LCP) System Recruiting NCT04092374
33 The Effects Of Casein Glycomacropeptide On Metabolic Control And General Health Status In Children And Adults With PKU: A Randomised Crossover Trial Recruiting NCT04076176
34 Randomzied Controlled Trial Comparing Tension Band Wiring and Plate Fixation in the Treatment of Olecranon Fractures in Adults Active, not recruiting NCT03280602
35 An Acceptability Study to Evaluate the Adherence, Tolerance and Metabolic Control of Patients With Tyrosinaemia When Using TYR Sphere (a Food for Special Medical Purposes) as Part of Dietary Management. Not yet recruiting NCT04761588

Search NIH Clinical Center for Lmna-Related Cardiocutaneous Progeria Syndrome

Sources

Genetic Tests for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section
Sources

Anatomical Context for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section

MalaCards organs/tissues related to Lmna-Related Cardiocutaneous Progeria Syndrome:

40
Liver, Heart, Bone, Retina, Lung, Colon, Pancreas
Sources

Publications for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section

Articles related to Lmna-Related Cardiocutaneous Progeria Syndrome:

(show top 50) (show all 275)
# Title Authors PMID Year
1
Cognitive Screening Tools for Late Career Physicians: A Critical Review. 61
32419575 2021
2
Excitons competition regulation via organic cation-site and halogen-site co-halogenation of (X-p-PEA)2Pb(Cl/Br)4 perovskites. 61
33429346 2021
3
BDBB: A Novel Beta-distribution-based Biclustering Algorithm for Revealing Local Co-methylation Patterns in Epi-transcriptome Profiling Data. 61
33764880 2021
4
The Association Between the Special Subsidy for Families Practicing Family Planning and the Mental Health of Loss/Disability-of-Single-Child Parents: Evidence from China. 61
32740691 2021
5
Metallosis after using distal fibular locking plate for lateral malleolar fractures: a retrospective study. 61
33646355 2021
6
In vivo study of hypericin-loaded poloxamer-based mucoadhesive in situ gelling liquid crystalline precursor system in a mice model of vulvovaginal candidiasis. 61
33626136 2021
7
Temporal organisation of the brain's intrinsic motor network: The relationship with circadian phenotype and motor performance. 61
33577933 2021
8
Liquid Crystalline Phases for Enhancement of Oral Bioavailability. 61
33619612 2021
9
Differences between Two Methods to Stabilize Supramalleolar Osteotomies in Children-A Retrospective Case Series. 61
33513700 2021
10
The Abundance and Structure of Deadwood: A Comparison of Mixed and Thinned Chinese Fir Plantations. 61
33746997 2021
11
Chemical Exchange of Hydroxyl Groups in Lipidic Cubic Phases Characterized by NMR. 61
33251799 2021
12
An implementation model for managing cloud-based longitudinal care plans for children with medical complexity. 61
33150404 2021
13
Liquid Crystalline Polymers: Opportunities to Shape Neural Interfaces. 61
33501705 2021
14
User-centered design of a longitudinal care plan for children with medical complexity. 61
33043368 2020
15
Host Differential Sensitization toward Color/Lifetime-Tuned Lanthanide Coordination Polymers for Optical Multiplexing. 61
32914560 2020
16
Demonstration of electron diffraction from membrane protein crystals grown in a lipidic mesophase after lamella preparation by focused ion beam milling at cryogenic temperatures. 61
33304220 2020
17
Derived high reducing sugar and lignin colloid particles from corn stover. 61
33303003 2020
18
Numerical investigation of mechanical behavior of human femoral diaphysis in normal and defective geometry: experimental evaluation. 61
33164564 2020
19
Effect of fish-oil supplementation on breastmilk long-chain polyunsaturated fatty acid concentration: a randomized controlled trial in rural Ethiopia. 61
33159163 2020
20
Wide Frequency Characterization of Intra-Body Communication for Leadless Pacemakers. 61
32167883 2020
21
Adaptions to the National Diabetes Prevention Programme lifestyle change curriculum by Hawai'i Federally Qualified Health Centers: a qualitative descriptive study. 61
33148728 2020
22
Characteristics of asbestos fibers in lung tissue from occupational and environmental asbestos exposure of lung cancer patients in Busan, Korea. 61
33230116 2020
23
Midline or long peripheral catheters in difficult venous access conditions? A comparative study in patients with acute cardiovascular diseases. 61
31973988 2020
24
Bioinspired light-driven soft robots based on liquid crystal polymers. 61
32779649 2020
25
Linear Coordination Polymer Synthesis from Bis-Catechol Functionalized RAFT Polymers. 61
32757259 2020
26
Femoral condylar locking compression plates: a case series. The Rural District General Hospital Experience. 61
33024539 2020
27
Could wild boar be the Trans-Siberian transmitter of African swine fever? 61
32866334 2020
28
Chemical structure elucidation of an inulin-type fructan isolated from Lobelia chinensis lour with anti-obesity activity on diet-induced mice. 61
32475601 2020
29
Does the use of locking plates or mesh and wires influence the risk of symptomatic non-union of the sternal osteotomy after modified Ravitch? 61
32802442 2020
30
Lamina cribrosa pore movement during acute intraocular pressure rise. 61
31488430 2020
31
Physiochemical Characterization and Stability of Lipidic Cubic Phases by Solution NMR. 61
32418433 2020
32
Dynamic Interfacial Regulation by Photodeformable Azobenzene-Containing Liquid Crystal Polymer Micro/Nanostructures. 61
32449856 2020
33
Evolution of SO2 and NOx Emissions from Several Large Combustion Plants in Europe during 2005-2015. 61
32455768 2020
34
Recurrence with malignancy after endoscopic resection of large colon polyps with high-grade dysplasia: incidence and risk factors. 61
32472496 2020
35
Lonicera caerulea L. Polyphenols Alleviate Oxidative Stress-Induced Intestinal Environment Imbalance and Lipopolysaccharide-Induced Liver Injury in HFD-Fed Rats by Regulating the Nrf2/HO-1/NQO1 and MAPK Pathways. 61
32250024 2020
36
Finite element analysis of bone and implant stresses for customized 3D-printed orthopaedic implants in fracture fixation. 61
32077012 2020
37
Human Circadian Phenotyping and Diurnal Performance Testing in the Real World. 61
32338646 2020
38
Synergetic Combination of Interfacial Engineering and Shape-Changing Modulation for Biomimetic Soft Robotic Devices. 61
32125871 2020
39
Mechanical comparison of two small interlocking nails in torsion using a feline bone surrogate. 61
31828811 2020
40
Detection of E. coli labeled with metal-conjugated antibodies using lateral-flow assay and laser-induced breakdown spectroscopy. 61
31989196 2020
41
Arthrodesis of the equine proximal interphalangeal joint: a biomechanical comparison of 2 different LCP systems. 61
32059234 2020
42
Assessing the Performance of Land Consolidation Projects in Different Modes: A Case Study in Jianghan Plain of Hubei Province, China. 61
32098225 2020
43
Usefulness of bilateral plate fixation for periprosthetic distal femur fracture after total knee arthroplasty. 61
32114351 2020
44
Temporal, Spatial, and Temperature Controls on Organic Carbon Mineralization and Methanogenesis in Arctic High-Centered Polygon Soils. 61
33505383 2020
45
Testing least cost path (LCP) models for travel time and kilocalorie expenditure: Implications for landscape genomics. 61
32960937 2020
46
Programmable 3D Shape-Change Liquid Crystalline Elastomer Based on a Vertically Aligned Monodomain with Cross-link Gradient. 61
31786930 2019
47
Photodeformable Azobenzene-Containing Liquid Crystal Polymers and Soft Actuators. 61
31595576 2019
48
Fragment specific fixation technique using 2.7 mm VA LCP for comminuted posterior wall acetabular fractures: a novel surgical technique. 61
31286182 2019
49
Solimonas fluminis has an active latex-clearing protein. 61
31485689 2019
50
Structure and electronic properties of rare earth DOBDC metal-organic-frameworks. 61
31603163 2019
Sources

Variations for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section
Sources

Expression for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section
Search GEO for disease gene expression data for Lmna-Related Cardiocutaneous Progeria Syndrome.
Sources

Pathways for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section
Sources

GO Terms for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section
Sources

Sources for Lmna-Related Cardiocutaneous Progeria Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....